Category Regulatory

Vetter Expands Global Clinical Manufacturing Network with Strategic Site Upgrades

Vetter Strengthens its Global Clinical Manufacturing Network with Strategic Site Enhancements Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), announced significant progress in the continued expansion of its global clinical manufacturing network. With the ongoing scale-up of its…

Read MoreVetter Expands Global Clinical Manufacturing Network with Strategic Site Upgrades

Genmab Reports Safety of Rina-S® Combo with Bevacizumab in Advanced Ovarian Cancer

Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer Genmab A/S announced today new datademonstrating thatrinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOPO1)-inhibitor antibody-drug conjugate (ADC), evaluated in…

Read MoreGenmab Reports Safety of Rina-S® Combo with Bevacizumab in Advanced Ovarian Cancer

Biofield Therapy Slows Pancreatic Cancer and Reduces Metastasis, Study Finds

Study Finds Biofield Therapy Slows Pancreatic Cancer Progression and Reduces Metastasis Biofield therapy (BT)—a non-invasive, practitioner-administered therapy—can significantly slow the growth and spread of pancreatic cancer in pre-clinical models, according to a new study led by researchers at The University…

Read MoreBiofield Therapy Slows Pancreatic Cancer and Reduces Metastasis, Study Finds

Covalon Technologies Ltd. Showcases Innovation and Infection Prevention at Infusion Nurses Society 2026 Annual Meeting

Covalon Technologies Ltd. Highlights Clinical Innovation and Infection Prevention Leadership at Infusion Nurses Society 2026 Annual Meeting Covalon Technologies Ltd., a company specializing in advanced medical technologies for wound care and infection prevention, has announced its participation in the Infusion…

Read MoreCovalon Technologies Ltd. Showcases Innovation and Infection Prevention at Infusion Nurses Society 2026 Annual Meeting

Ossium Health Welcomes Indiana Governor Mike Braun and Healthcare Leaders for Facility Tour and Reception

Ossium Health Welcomes Indiana Governor Mike Braun and Healthcare Leaders for Facility Tour and Reception Ossium Health recently opened its doors to state officials, healthcare leaders, and members of the regional life sciences community for a special facility tour and…

Read MoreOssium Health Welcomes Indiana Governor Mike Braun and Healthcare Leaders for Facility Tour and Reception

CMS Assigns COVID-19–Specific HCPCS Codes for Fresenius Kabi’s Tyenne® (tocilizumab-aazg)

Fresenius Kabi Receives CMS Approval for COVID-19 Indication-Specific HCPCS Codes for Tyenne® (tocilizumab-aazg) Fresenius Kabi, a subsidiary of Fresenius and a global leader in essential medicines and medical technologies, has announced a significant reimbursement milestone for its biologic therapy Tyenne®…

Read MoreCMS Assigns COVID-19–Specific HCPCS Codes for Fresenius Kabi’s Tyenne® (tocilizumab-aazg)

Pilatus Biosciences to Present Sex-Specific CD36 Antibody Data in Colorectal Cancer at AACR 2026

Pilatus Biosciences to Showcase New Data on Sex-Specific Efficacy of CD36-Targeting Antibody in Colorectal Cancer at AACR 2026 Pilatus Biosciences has announced that it will present new preclinical findings at the upcoming AACR Annual Meeting 2026, scheduled to take place…

Read MorePilatus Biosciences to Present Sex-Specific CD36 Antibody Data in Colorectal Cancer at AACR 2026

Shionogi & Co., Ltd. Awarded U.S. Government Contract via BARDA Project BioShield for Drug-Resistant Bacterial Preparedness

Shionogi & Co., Ltd. Secures U.S. Government Contract via BARDA Project BioShield to Strengthen Preparedness Against Drug-Resistant Bacterial Threats Shionogi & Co., Ltd. has announced that its U.S.-based subsidiary, Shionogi Inc., has been awarded a significant federal contract under Biomedical…

Read MoreShionogi & Co., Ltd. Awarded U.S. Government Contract via BARDA Project BioShield for Drug-Resistant Bacterial Preparedness

United Therapeutics Corporation Receives U.S. Food and Drug Administration RMAT Designation for miroliverELAP® in Acute Liver Failure

United Therapeutics Corporation Receives U.S. Food and Drug Administration Regenerative Medicine Advanced Therapy (RMAT) Designation for miroliverELAP® in the Treatment of Acute Liver Failure United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation focused on developing innovative therapies for end-stage…

Read MoreUnited Therapeutics Corporation Receives U.S. Food and Drug Administration RMAT Designation for miroliverELAP® in Acute Liver Failure